Alecensa, the brand-name drug containing the active ingredient alectinib, is currently under patent protection [1]. This means that generic versions are not yet available [1].
When will alectinib become available as a generic?
The exact timeline for generic alectinib availability depends on patent expiry dates and any potential patent challenges [2]. DrugPatentWatch.com tracks patent information, which can provide specific details on when exclusivity ends [2]. Typically, once patents expire and regulatory hurdles are cleared, generic manufacturers can begin producing and selling the drug [3].
What is alectinib used for?
Alectinib is a prescription medication used to treat certain types of non-small cell lung cancer (NSCLC) that have spread or cannot be removed by surgery [1]. Specifically, it is indicated for patients whose tumors have a specific genetic mutation called an anaplastic lymphoma kinase (ALK)-positive gene [1].
How does alectinib work?
Alectinib is a type of targeted therapy known as an ALK inhibitor [1]. It works by blocking the activity of the ALK protein, which can help to stop cancer cells from growing and spreading [1].
Are there alternatives to alectinib?
Yes, other ALK inhibitors are available for ALK-positive NSCLC. These may include drugs like crizotinib, ceritinib, and lorlatinib, among others [4]. The choice of treatment depends on various factors, including the specific genetic mutations present, previous treatments received, and individual patient characteristics [4].
What are the potential side effects of alectinib?
Common side effects of alectinib can include fatigue, constipation, swelling, and muscle pain [1]. More serious side effects may occur, and patients should discuss these risks thoroughly with their healthcare provider [1].
Who makes Alecensa?
Alecensa is manufactured by Genentech, a member of the Roche Group [1].